{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260407155688/en/Enanta-Pharmaceuticals-to-Present-Data-for-Zelicapavir-an-Oral-Once-Daily-N-Protein-Inhibitor-in-Development-for-the-Treatment-of-Respiratory-Syncytial-Virus-at-ESCMID-Global-2026", "message": "News view counter 650632 successfully enlarged"}